Prosecution Insights
Prosecution Insights
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| No statute on record | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 1 | 44.6% | +32.4% |
| TAYLOR, LIA ELAN | 1 | 64.0% | +28.2% |
| BERHANE, SELAM | 1 | 61.3% | +55.5% |
| CHASE, CAROL ANN | 1 | 44.6% | +83.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18645607 | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases | DENT, ALANA HARRIS | 60d overdue |
| 18644720 | METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER | TAYLOR, LIA ELAN | 38d overdue |
| 17414968 | BIFUNCTIONAL MOLECULE DIRECTED AGAINST HUMAN PD-1 | CHASE, CAROL ANN | 18d overdue |
| 18060129 | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| 1641 | 1 |
| 1675 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18645607 | Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | 60d overdue | Pending | Apr 25, 2024 |
| 18644720 | METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER | TAYLOR, LIA ELAN | 1641 | Other | Non-Final OA | 38d overdue | Pending | Apr 24, 2024 |
| 18060129 | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent | BERHANE, SELAM | 1675 | Other | Final Rejection | — | Pending | Nov 30, 2022 |
| 17414968 | BIFUNCTIONAL MOLECULE DIRECTED AGAINST HUMAN PD-1 | CHASE, CAROL ANN | 1646 | Other | Final Rejection | 18d overdue | Pending | Jun 17, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial